Form 4: NKGen Biotech CEO Acquires Shares and Warrants in Recent Transaction

NKGen Biotech's CEO, Paul Y. Song, recently acquired shares and warrants of the company's common stock.

Summary

• On May 5, 2025, Paul Y. Song, the CEO of NKGen Biotech, purchased 20,849,725 shares of the company's common stock at a price of $0.1271 per share.
• The purchase was made pursuant to a Securities Purchase Agreement (SPA).
• In addition to the shares, Mr. Song also acquired 41,699,449 warrants to purchase shares of common stock, also in connection with the SPA.
• The warrants have an exercise price of $0.1271 and expire on May 5, 2030.

Sentiment

Score: 7

Explanation: The CEO's purchase of shares and warrants is generally a positive signal, suggesting confidence in the company's future. However, the document itself is simply a factual report of the transaction.

Positives

• The CEO's investment could be seen as a sign of confidence in the company's future prospects.

Industry Context

This type of transaction, where a CEO increases their stake in the company, is common in the biotech industry. It can signal confidence in the company's pipeline and future prospects.

Stakeholder Impact

• Shareholders may view the CEO's purchase as a positive sign.
• The increased ownership stake aligns the CEO's interests more closely with those of the shareholders.

Key Dates

Keywords

NKGen Biotech, Paul Y. Song, common stock, warrants, acquisition, Securities Purchase Agreement, NKGN, CEO